Carbonic Anhydrase Inhibitor Drug Class List

Drugs in Drug Class: Carbonic Anhydrase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	ACETAZOLAMIDE	acetazolamide	CAPSULE, EXTENDED RELEASE;ORAL	210423-001	Feb 19, 2019	AB	RX	No	No
Cadila	ACETAZOLAMIDE	acetazolamide	CAPSULE, EXTENDED RELEASE;ORAL	205301-001	Jan 16, 2019	AB	RX	No	Yes
Novast Labs	ACETAZOLAMIDE	acetazolamide	CAPSULE, EXTENDED RELEASE;ORAL	203434-001	Sep 30, 2016	AB	RX	No	No
Accord Hlthcare	ACETAZOLAMIDE	acetazolamide	CAPSULE, EXTENDED RELEASE;ORAL	207659-001	Oct 18, 2018	AB	RX	No	No
Heritage Pharma	ACETAZOLAMIDE	acetazolamide	TABLET;ORAL	205530-001	Oct 27, 2016	AB	RX	No	No

Market Dynamics and Patent Landscape for Carbonic Anhydrase Inhibitors

Last updated: April 26, 2026

Carbonic anhydrase inhibitors (CAIs) target the reversible catalysis of CO2 hydration and are used across ophthalmology, neurology, oncology, and altitude/edema-related indications. The IP landscape is fragmented by drug class (sulfamates, sulfones), by indication (glaucoma vs epilepsy vs oncology), and by the use of different salts, polymorphs, and fixed-dose combinations. Commercially, established brands in ophthalmology anchor demand, while newer agents and reformulations drive incremental patent life in the EU and US.

How big is the carbonic anhydrase inhibitor opportunity and where does demand concentrate?

Sales concentration by therapeutic area

Commercial CAIs are dominated by:

• Ophthalmology (glaucoma and ocular hypertension): chronic, high-retention use and strong payer coverage for standard-of-care regimens.
• Neurology (epilepsy): chronic use patterns but smaller absolute market size than glaucoma.
• Other uses (rare and niche): altitude sickness prevention and adjunct diuretic/edema contexts in some geographies; oncology applications are smaller and more dependent on clinical trial outcomes and partner licensing.

Commercial drivers

Market dynamics are shaped by:

• Chronic administration and adherence: glaucoma regimens are long-duration; this increases the value of formulation and dosing convenience.
• Local competition via generics and reformulations: once APIs go generic, value shifts to branded formulations, combination products, and extended-release.
• Regulatory arbitrage across formulations: topical ophthalmics and systemic capsules/combinations can enjoy different regulatory and exclusivity paths even when the core API is off-patent.

Which carbonic anhydrase inhibitors define the competitive field today?

Core CAI active ingredients (typical market anchors)

The CAI market is built around several widely used molecules. The leading historical and commercial agents include:

• Acetazolamide
• Brinzolamide (topical ophthalmic)
• Dorzolamide (topical ophthalmic)
• Methazolamide
• Topiramate (systemic CAI activity; epilepsy focus)
• Tuzistra-like newer ophthalmic CAIs in some markets (varies by region and product lifecycle)

What changes the competitive balance

• Topical ocular CAIs face fast generic entry once patent barriers clear for drug product and methods. Brands defend via:
  • fixed dosing regimens and multi-ingredient drops,
  • preservative systems and viscosity modifiers,
  • device and packaging exclusivity where available.
• Systemic CAIs (acetazolamide/methazolamide) face fewer product variants but still see lifecycle management via new salt forms, dosing regimens, and combination therapy.

What patent themes recur across carbonic anhydrase inhibitors?

Patent strategy in CAIs typically clusters into four buckets:

1. Composition of matter (CoM) and derivatives: new CAI scaffolds and substitutions, often targeting selectivity or potency.
2. Pharmaceutical compositions: salts, hydrates, polymorphs, solvates, and specific formulation compositions for stability and bioavailability.
3. Methods of treatment: patient populations, dosing regimens, and indication-specific methods (glaucoma subtypes, refractory epilepsy).
4. Use in combinations: fixed-dose combinations (FDCs) and combination regimens with other ocular hypotensives (for topical) or anticonvulsants (for systemic).

Lifecycle levers that actually move outcomes

• Drug product protection in ophthalmology can outlast API patents if the claim coverage ties to:
  • particle size or polymorph,
  • suspension uniformity and stability,
  • excipient system and viscosity,
  • packaging and delivery.
• Method-of-treatment claims can preserve value where clinical use patterns become definable and enforceable, especially if backed by responder subgroups or defined dosing schedules.

Where is the patent landscape most congested: eyes vs systemic?

Ophthalmology: dense but fragmented

Ocular CAIs attract:

• local formulation patents (drug product and method),
• combination product filings (FDC with beta-blockers, prostaglandin analogs, or alpha agonists),
• polymorph and stability claims.

Because topical markets are competitive, patenting is frequent but litigated less often; enforcement tends to occur around:

• generic approvals,
• “skinny labeling” and method carve-outs,
• bioequivalence and formulation similarity.

Systemic: fewer molecules, more derivative and regimen coverage

For systemic CAIs and CAI-active molecules (notably topiramate), patenting often shifts to:

• dosing regimens and titration,
• specific patient subpopulations,
• combination therapies for seizure syndromes.

What does the enforcement and regulatory pathway mean for generic entry risk?

US generic risk model (high level)

In the US, the key pressure points are:

• Hatch-Waxman Paragraph IV filings challenging unexpired patents,
• Orange Book patent lists that define the litigation landscape,
• label carve-outs that reduce generic liability.

Where the innovator relies on method-of-treatment patents, entry risk rises if generic label design can avoid practicing the patented steps.

EU market structure

In the EU, entry risk depends on:

• national EP validations,
• supplementary protection certificate (SPC) availability for drug products,
• enforcement capacity across member states.

Lifecycle extensions in the EU frequently depend on whether the first marketing authorization and SPC eligibility align with the claimed compound and filing date.

How do CAI patent clusters map to major molecules?

Acetazolamide and methazolamide

• These older CAIs are widely generic in most markets.
• Remaining value is driven by:
  • region-specific brand positioning,
  • formulation differentiation,
  • combination products (where clinically adopted).

From a patent standpoint, these molecules are generally not the center of future CoM battles. The remaining patent value is often in:

• particular formulation improvements,
• combination/regimen claims.

Dorzolamide and brinzolamide

Topical CAIs are typically where the patent landscape is most active historically due to:

• multiple reformulation paths (suspensions vs solutions),
• stability and delivery systems,
• device-like features in some product lines.

As API patents expire, drug product and method-of-use patents determine when generics gain full substitution.

Topiramate (CAI activity)

Topiramate is a systemically delivered CAI with:

• extensive patent history across formulations and uses,
• a mature generic market in many regions.

Future patent value is less about the core CAI mechanism and more about:

• new combinations,
• specific epilepsy subtypes and dosing strategies,
• extended-release formulations where supported by claimed stability and release profiles.

What are the main market dynamics affecting R&D investment decisions?

1) Patent cliffs drive product portfolio churn

CAI pipelines are shaped by:

• expiring ophthalmic patents that shift revenue from branded drops to generics,
• the cost of proving incremental clinical benefit when mechanism is already validated.

2) Formulation and combination may beat “new MOA”

For CAIs, the highest probability of commercial differentiation tends to be:

• better adherence via dosing simplification,
• more tolerable topical formulations (lower stinging, better stability),
• combination regimens that improve IOP control or seizure control.

3) Regulatory strategy is as important as chemistry

Investors typically prioritize programs where:

• there is a clear path to label expansion,
• the regulatory package can support additional exclusivity windows,
• the IP portfolio includes both CoM and drug product claims, not only methods.

Where is the next patent opportunity likely to come from?

Patent opportunity in CAIs most often arises from:

• topical ocular formulations with improved stability, particle engineering, and consistent release under real-world storage conditions,
• fixed-dose combinations with other glaucoma drugs that can be defended via:
  • composition claims tying both active agents to specific excipient and concentration ranges,
  • method claims defined by dosing sequences and IOP response targets,
• controlled-release systemic formulations that reduce dosing frequency and improve adherence in epilepsy or other chronic CAI applications,
• new patient selection or responder definitions that convert method claims into enforceable clinical practice.

Key Takeaways

• Demand concentrates in ophthalmology (glaucoma/ocular hypertension) with chronic use driving value.
• The CAI patent landscape is fragmented by molecule, formulation, and indication, with ophthalmic drug product and combination patents often providing the most enforceable lifecycle value.
• Generic entry risk rises when innovators rely primarily on method-of-treatment patents that can be designed around via label carve-outs.
• Future upside most likely comes from formulation differentiation and combination regimens that can be protected as composition and drug product claims, not only as generic “use” statements.
• Investment screening should prioritize portfolios that include both: (1) enforceable drug product CoM and (2) indication-relevant method claims backed by clinical rationale.

FAQs

1) What makes carbonic anhydrase inhibitors different from other ophthalmic classes in patent strategy?

Topical CAIs attract heavy lifecycle activity through formulation, stability, and combination products, so enforceable value can shift from API patents to drug product and method coverage.

2) Are new CAI molecules the most likely route to defensible revenue?

Not usually. Market behavior favors incremental formulation or combination strategies that can extend exclusivity and reduce generic substitution.

3) What drives generic substitution risk the fastest in topical CAIs?

The speed of entry depends on how tightly the innovator’s claims cover drug product specifics (polymorph, particle size, suspension/excipient system) versus broad method statements.

4) Does the patent landscape differ materially between US and EU for CAIs?

Yes. US value is tied to Orange Book-listed patents and Hatch-Waxman litigation posture, while the EU outcome depends heavily on SPC eligibility and national EP validations.

5) Which CAI applications are most investable right now: glaucoma or systemic?

Glaucoma tends to be more investable for near-term commercial scale, while systemic programs require more careful differentiation around dosing, combinations, and formulation convenience.

---

References

[1] European Medicines Agency (EMA). “Supplementary protection certificates (SPCs).” European patent and regulatory guidance. https://www.ema.europa.eu/ (accessed 2026-04-26).
[2] FDA. “Hatch-Waxman Drug Patent Certification and Guidance.” U.S. Food and Drug Administration. https://www.fda.gov/ (accessed 2026-04-26).
[3] FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-04-26).